

IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striketrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (original) A method of treating A-V graft failure in a subject in need of such treatment, said method comprising administering an effective amount of an agent that inhibits the production, release, or neo-intima generating effects of chymase to said subject, wherein said effective amount of said agent is an amount effective to treat said A-V graft failure.
2. (original) A method according to claim 1 wherein said A-V graft failure comprises intimal hyperplasia.
3. (original) A method of treating intimal hyperplasia associated with an A-V graft, said method comprising administering an agent that inhibits the production, release or neo-intima generating effects of chymase.
4. (currently amended) A method according to claim 1 ~~any one of claims 1-3~~, wherein said agent is N-(3,4-dimethoxycinnamoyl)anthranilic acid, or a pharmaceutically acceptable salt thereof.
5. (currently amended) A method according to claim 1 ~~any one of claims 1-3~~, wherein said agent is an angiotensin II receptor antagonist.
6. (currently amended) A method according to claim 1 ~~any one of claims 1-3~~, wherein said agent is a chymase inhibitor.
7. (currently amended) A method according to claim 6, wherein said chymase inhibitor is 2-(5-formylamino-6-oxo-3-phenyl-1,6-dihydropyrimidine-1-yl)-N-{2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl}hexyl acetamide, or a pharmaceutically acceptable salt thereof.
8. (currently amended) A method according to claim 1 ~~any one of claims 1-3~~, wherein said subject is human.

9. (currently amended) A method according to claim 1 ~~any one of claims 1-3~~, wherein said treatment comprises inhibition of intimal hyperplasia.
10. (original) A method according to claim 9, wherein said intimal hyperplasia comprises the proliferation and migration of smooth muscle cells.
11. (original) A method according to claim 9, wherein said intimal hyperplasia occurs at the venous end of said A-V graft.
12. (currently amended) A method according to any one of claims 8 – 11, wherein said agent is ~~elastase inhibitor~~ is 2-(5-formylamino-6-oxo-3-phenyl-1,6,-dihydropyrimidine-1-yl)-N-{2,3-dioxo-6-(2-pyridyloxy)-1-phenylmethyl}hexyl acetamide, or a pharmaceutically acceptable salt thereof.